Journal
PARKINSONISM & RELATED DISORDERS
Volume 18, Issue 5, Pages 585-589Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2012.03.003
Keywords
Parkinson's; Ageism; Research; Elderly; Exclusion
Categories
Funding
- GlaxoSmithKline
- Orion Pharma
- Teva-Lundbeck Pharmaceuticals
Ask authors/readers for more resources
Background: The exclusion of older participants from clinical research is common and limits the generalisation of research findings. We aimed to assess the current potential for older patients to participate in Parkinson's disease (PD) research. Method: We performed a systematic analysis of data extracted from the World Health Organization Clinical Trials Registry Platform regarding 206 actively recruiting PD research studies. Data regarding study variables and exclusion on the grounds of an upper age limit was extracted from each registry entry and subsequently used for statistical analysis. Results: Exclusion by arbitrary upper age limit is common, with 101 (49%) of studies excluding participants by age and with a mean upper age limit for exclusion of 79.3 years (range 64-95 years). Exclusion by age was significantly more common in studies with an estimated enrolment of fewer than 100 participants; OR 1.92 (95%Cl 1.13-3.42) P = 0.018. Rates of exclusion by age were not significantly influenced by study subject, study location, source of funding, study duration or number of centres. Conclusion: Exclusion of participants from PD research on the basis of an upper age limit is common and particularly problematic in smaller studies. The exclusion of older participants seriously compromises the generalisation of findings from PD research to the large numbers of elderly PD patients seen in clinical practice. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available